Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Other autoinducer-2 receptor refers to a diverse group of bacterial proteins that recognize the universal quorum-sensing signal autoinducer-2 (AI-2), distinct from the well-characterized LuxP and LsrB families (Source: NIH, Frontiers in Microbiology). These receptors include the ribose-binding protein RbsB, the histidine kinase AsrK, and various chemoreceptors such as PctA and TlpQ, which allow a wide range of bacteria to sense and respond to interspecies communication (Source: NIH, ACS Chemical Biology). AI-2 is a byproduct of the activated methyl cycle, and its perception by these receptors regulates critical processes such as biofilm formation, motility, and the expression of virulence factors (Source: NIH, Journal of Bacteriology). Because AI-2 signaling is central to bacterial coordination and pathogenesis, these receptors are attractive targets for pathoblocker or anti-virulence therapies (Source: NIH, MDPI). Small molecule inhibitors, often structural analogs of the AI-2 precursor DPD, can competitively bind to these receptors to disrupt quorum sensing without killing the bacteria, potentially reducing the selective pressure for antibiotic resistance (Source: ACS Chemical Biology). However, the high conservation of binding domains among different sugar-binding proteins and the potential for disrupting beneficial commensal bacteria present significant therapeutic challenges (Source: NIH, Nature Communications).
Quorum sensing inhibition via competitive antagonism of AI-2 binding sites or modulation of downstream signal transduction pathways, thereby preventing the activation of virulence and biofilm-related genes.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Other autoinducer-2 receptor.